Form D · Biotechnology
iXpressGenes, Inc.
Huntsville, AL · CIK 0002074283
Offering snapshot reported Jun 26, 2025 · SEC filing
- Reported sold
- $2.37M Offering amount: $4.18M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 16, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 26, 2025 | Initial | $2,370,000 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-549995
Source: Form D, filed Jun 26, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Barbara Fisk | Director |
| Joseph Ng | Director, Executive |
| Peggy Sammon | Director |
| John Schmitt | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
601 Genome Way Northwest
Huntsville, AL, 35806
Huntsville, AL, 35806